Vaccines against Clostridium perfringens Alpha-toxin

Author(s): Masahiro Nagahama

Journal Name: Current Pharmaceutical Biotechnology

Volume 14 , Issue 10 , 2013

Become EABM
Become Reviewer
Call for Editor


Clostridium perfringens alpha-toxin is thought to be an important agent in gas gangrene, which is a lifethreatening infection with fever, pain, edema, myonecrosis, and gas production. The toxin (370 residues) is composed of an N-terminal domain (1-250 residues, N-domain) in which the catalytic site is found and a C-terminal domain (251-370 residues, C-domain) responsible for binding to membranes. During the past decade, recombinant DNA technology has been employed to develop second-generation vaccines, including site-directed mutants and the C-domain of the toxin, to prevent gas gangrene. These immunities have led to protection against the lethal effects of wild-type C. perfringens in mice. C-domain vaccines are capable of protecting against heterologous clostridia causing clostridial myonecrosis. This article summarizes the current knowledge on vaccines against alpha-toxin.

Keywords: Alpha-toxin, C-domain, Clostridium perfringens, Gas gangrene, Recombinant vaccine.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 26 December, 2013
Page: [913 - 917]
Pages: 5
DOI: 10.2174/1389201014666131226124348
Price: $65

Article Metrics

PDF: 37